Cases of idiopathic pulmonary fibrosis (IPF) may be caused by exposure to asbestos, as suggested by a recent study conducted at Imperial College London in the United Kingdom, and presented at the European Respiratory Society’s conference. The new mortality data about IPF, asbestosis, and mesothelioma may offer new information for how to…
News
The clinical stage specialty pharmaceutical company Pacific Therapeutics announced that is looking for a commercialization partner for the sale of PTL-202, as a result of positive results of recent pre-clinical studies and an initial phase I clinical trial of its lead drug candidate for pulmonary fibrosis. PTL-202 is a combination of…
Pacific Therapeutics Ltd., a pharmaceutical company focused on the reformulation of existing approved drugs, recently announced the end of an initial phase 1 trial of its drug candidate for Idiopathic Pulmonary Fibrosis, PTL-202, combined with an important antioxidant amino acid, with positive signs on its effectiveness, low side effects,…
Citizens of Canada’s largest province afflicted by idiopathic pulmonary fibrosis (IPF) have finally been given access to a key IPF therapy after a protracted two-year fight. IPF patients in Canada’s other provinces hope publicly-funded access to first and only treatment isn’t far behind. Ontario’s Executive Officer has announced that Esbriet…
Representatives from Boehringer Ingelheim will be presenting 18 abstracts containing data from idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), and asthma trials conducted with compounds developed by the company at the European Respiratory Society (ERS) to be held at the end of this week. The rare disease insights…
MediciNova, a biopharmaceutical company focused on developing therapies to fulfill unmet needs in respiratory, neurological, and liver diseases, recently announced that it will present at the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF) on September 23rd in Mont Tremblant, Canada. According to a recent press release, the presentation…
Plant-based biotechnology company iBio, specializing in developing and manufacturing biological products, was recently granted notices of intention for two European patent applications claiming novel protein expression technologies. iBio is also currently developing a proprietary product for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, among other fibrotic diseases using…
Sorrento Therapeutics, Inc., a company working on the development of new treatments for cancer and its associated pain, has recently received a Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI), a division of the NIH, to advance its research on an immunotherapy…
An advocacy group associated with the Coalition for Pulmonary Fibrosis (CPF) called The Daughters of PF engaged in a national awareness campaign to raise awareness of pulmonary fibrosis, beginning in the Atlanta area and taking place during National Pulmonary Fibrosis Month, which starts in September. The first event organized was last Sunday, when the members of group dressed…
